Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript

Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript

Seeking Alpha • 4 hours ago

NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript

NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript

Seeking Alpha • Apr 29, 2026

NeoGenomics Reports First Quarter 2026 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.

Business Wire • Apr 28, 2026

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' oncology testing portfolio is now available through Epic Aura.

Business Wire • Apr 23, 2026

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026.

Business Wire • Apr 13, 2026

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls.

Business Wire • Apr 7, 2026

Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript

Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 19, 2026

NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.

Business Wire • Mar 16, 2026

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.

Business Wire • Feb 25, 2026

After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)

NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Feb 20, 2026